Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published review analyses for the evaluation of reimbursement applications:
- Keytruda (pembrolizumab) in the treatment of lung cancer and pleural mesothelioma in follow-up treatment
- Keytruda (pembrolizumab) in the treatment of lung cancer and pleural mesothelioma in perioperative treatment
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.